首页> 美国卫生研究院文献>American Health Drug Benefits >Effectiveness of Anti-Tumor Necrosis Factor Agents in the Treatment of Rheumatoid Arthritis: Observational Study

【2h】

Effectiveness of Anti-Tumor Necrosis Factor Agents in the Treatment of Rheumatoid Arthritis: Observational Study

机译：抗肿瘤坏死因子药物治疗类风湿关节炎的疗效：观察性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveThe efficacy of anti-tumor necrosis factor therapies in rheumatoid arthritis has been demonstrated in randomized clinical trials. The purpose of the present study was to evaluate the effectiveness of these agents for the treatment of rheumatoid arthritis in a real-world setting.

机译：目的在随机临床试验中证实了抗肿瘤坏死因子疗法在类风湿关节炎中的疗效。本研究的目的是评估这些药物在现实环境中治疗类风湿关节炎的有效性。

著录项

期刊名称 American Health Drug Benefits
作者
Anna DSouza; Brian L. Meissner; Boxiong Tang; R. Scott McKenzie; Catherine T. Piech; Matthew Mitchell;
展开▼
作者单位

展开▼
年(卷),期 2010(3),4
年度 2010
页码 266–273
总页数 8
原文格式 PDF
正文语种
中图分类药学;
关键词

相似文献

外文文献
中文文献
专利

1. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. [J] . Barra L, Pope JE, Payne M The Journal of rheumatology . 2009,第7期

机译：类风湿性关节炎，银屑病关节炎和强直性脊柱炎的抗肿瘤坏死因子治疗的现实世界：根据改善健康评估调查表所需治疗的数量得出的成本效益。
2. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-a agents in patients with rheumatoid arthritis: a retrospective chart review analysis [J] . Han-Na Lee, Yun-Kyung Kim, Geun-Tae Kim, Rheumatology international. . 2019,第5期

机译：中性粒细胞到淋巴细胞和血小板到淋巴细胞比例作为预测因子为12周治疗反应和抗肿瘤坏死因子的药物持续性 - 类风湿性关节炎患者的药剂：回顾性图表审查分析
3. Treatment with anti-tumor necrosis factor biologic agents in human T lymphotropic virus type I-positive patients with rheumatoid arthritis [J] . UmekitaK., HidakaT., MiyauchiS., Arthritis care & research . 2014,第5期

机译：抗肿瘤坏死因子生物制剂治疗类风湿性关节炎I型人T淋巴细胞阳性患者
4. RHEUMATOID FACTOR-CORRELATED PROTEINS IS COMPLEMENTARY BIOMARKER OF RHEUMATOID ARTHRITIS [C] . Hee-Gyoo Kang, Sora Mun, Arum Park, International Mass Spectrometry Conference . 2018

机译：类风湿因子相关蛋白是类风湿性关节炎的互补生物标志物
5. Predictors of Infection in Rheumatoid Arthritis Patients Using Anti-Tumor Necrosis Factor Agents [D] . Liu, Tasia 2017

机译：类风湿关节炎患者使用抗肿瘤坏死因子药物的感染预测因子
6. Comparative effectiveness of antitumour necrosis factor agents biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland [O] . A Finckh, C Tellenbach, L Herzog, 2020

机译：抗溃疡坏死因子剂生物学的对比效果在瑞士风湿性关节炎患者的术语队列中的替代作用和Tofacitinib中的替代作用方式
7. PMS38 COST-EFFECTIVENESS OF RITUXIMAB VERSUS ALTERNATIVE ANTI-TUMOR NECROSIS FACTOR (TNF) THERAPY AFTER PREVIOUS FAILURE OF ONE ANTI-TNF AGENT FOR TREATMENT OF RHEUMATOID ARTHRITIS IN MEXICO [O] . Carlos F 2010

机译：一位风湿关节炎患者过早失败后，利妥昔单抗对替代抗肿瘤坏死因子（TNF）治疗的PMS38成本效益

Effectiveness of Anti-Tumor Necrosis Factor Agents in the Treatment of Rheumatoid Arthritis: Observational Study

摘要

著录项

相似文献

相关主题

期刊订阅